Concepedia

Phillip Banks

PB

39

Publications

3.8K

Citations

27

H-Index

1992

Active since

Affiliations

Lexicon Pharmaceuticals (United States)(Current)

The University of Texas Southwestern Medical Center

University of Southern California

University of Toronto

Dallas Diabetes Research Center

Phillip Banks is an author at Lexicon Pharmaceuticals (United States) specializing in medicine, pharmacology, and diabetes.

ORCID

Top concepts

Publications per year

1992–2025

39

Publications

39

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes

Satish K. Garg, Robert R. Henry, Phillip Banks et al. · New England Journal of Medicine · 2017 · 400 citations · Full text

A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.

William R. Vogler, E Vélez-García, Roy S. Weiner et al. · Journal of Clinical Oncology · 1992 · 370 citations

A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis

Michael Safdi, Michael DeMicco, Charles A. Sninsky et al. · Gastroenterology · 1995 · 324 citations

, , +5

Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome

Matthew H. Kulke, Dieter Hörsch, Martyn Caplin et al. · Journal of Clinical Oncology · 2017 · 299 citations · Full text

LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial

Brian Zambrowicz, J Freiman, Phil Brown et al. · Clinical Pharmacology & Therapeutics · 2012 · 235 citations · Full text

Rows per page

1–5 of 39